Compare COFS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | CADL |
|---|---|---|
| Founded | 1898 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 578.8M |
| IPO Year | 1995 | 2021 |
| Metric | COFS | CADL |
|---|---|---|
| Price | $30.60 | $8.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $34.00 | $19.00 |
| AVG Volume (30 Days) | 60.6K | ★ 2.2M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $227,624,000.00 | $125,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $34.73 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $4.35 |
| 52 Week High | $33.58 | $9.27 |
| Indicator | COFS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 68.29 |
| Support Level | $29.51 | $4.80 |
| Resistance Level | $30.86 | $9.27 |
| Average True Range (ATR) | 0.74 | 0.60 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 27.56 | 75.28 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.